# A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants

> **NCT05603312** · PHASE1,PHASE2 · COMPLETED · sponsor: **MeiraGTx, LLC** · enrollment: 14 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **GENETIC:** AAV-GAD Low Dose
- **GENETIC:** AAV-GAD High Dose
- **PROCEDURE:** Sham Surgery

## Key facts

- **NCT ID:** NCT05603312
- **Lead sponsor:** MeiraGTx, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-05
- **Primary completion:** 2024-09-06
- **Final completion:** 2024-09-06
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05603312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05603312, "A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05603312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*